ALLO-501,allo-501A
allogene therapeutics
['lymphoma', '$allo']
$allo presents updated allo-501/501a phase 1 data in large b cell lymphoma at #asco23 67% orr and 58% cr rate.
five patients (42%) maintained a cr at month 6; four of five crs (80%) ongoing beyond six months, including two at 30+ months and one at 24+ months 
Investor/trader focused primarily in the biopharma sector. 
Tweets are not investment advice and are not recommendations of any kind.